Zarife Sahenk
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
215
Citations
11,419
Est. group size
~2
Recurring co-author estimate
Active years
51
Publishing since 1976
This researcher develops and tests gene therapy approaches for inherited and age-related neuromuscular diseases, including muscular dystrophies, Charcot-Marie-Tooth neuropathy, and inclusion body myositis, largely using mouse models. The work also includes clinical studies evaluating gene therapy outcomes and diagnostic classification in human patients with muscle and nerve disorders, such as Duchenne muscular dystrophy and multisystem proteinopathy.
Publication output has fluctuated over the past decade, peaking in 2017 and 2023, with a somewhat lower but steady pace in recent years averaging about 5 papers annually.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Autophagy activation via BAG3 gene therapy improves phenotype in a mouse model of LGMD1A
Molecular Therapy Advances · 2026
- AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A
International Journal of Molecular Sciences · 2026
- The <i>NORAD</i> -Pumilio regulatory axis in the evolution of inclusion body myositis
Journal of Neuropathology & Experimental Neurology · 2026
- Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study
Muscle & Nerve · 2026
- AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis
Human Gene Therapy · 2026
- AAV1.NT3 gene therapy mitigates the severity of autoimmune encephalomyelitis in the mouse model for multiple sclerosis
Gene Therapy · 2025
- Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy
Neurology Genetics · 2025
- Validity and Reliability of Clinical and Patient‐Reported Outcomes in Multisystem Proteinopathy 1
Annals of Clinical and Translational Neurology · 2025
- AAV1.tMCK.NT-3 gene therapy improves phenotype in <i>Sh3tc2−/−</i> mouse model of Charcot–Marie–Tooth Type 4C
Brain Communications · 2024
- REMEDY: A Novel CRISPR-based Allele Specific Approach Corrects VCP Mutations (S21.006)
Neurology · 2024
- Concurrent nodular lymphocytic myositis and myasthenia gravis. A case report
Neuromuscular Disorders · 2024
- AAV1.NT-3 gene therapy prevents age-related sarcopenia
Aging · 2023
- Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy
Neurology Genetics · 2023
- AAV1.NT‐3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia
Journal of Cachexia Sarcopenia and Muscle · 2023
- P56 Preliminary study of anti-AAVrh74 seroprevalence following gene transfer
Neuromuscular Disorders · 2023
- Neuromuscular Disorders×16
- Neurology×11
- Gene Therapy×3
- Molecular Therapy×2
- Muscle & Nerve×2
- Jerry R. Mendell
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Paul T. Martin
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Louise R. Rodino‐Klapac
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Renzhi Han
Biochemistry, Genetics and Molecular Biology · Indiana University
- Tatyana A. Vetter
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile